241
Participants
Start Date
February 13, 2019
Primary Completion Date
July 10, 2025
Study Completion Date
July 31, 2028
Radiation Therapy
This phase II study will evaluate whether a reduction in the RT dose, concomitant with a decrease in the RT field size, in patients that achieve complete response and have a negative post-chemotherapy PET scan following 3 to 6 cycles of rituximab containing chemotherapy, will be associated with a low risk of in-field failure. The goal of this approach is to maintain excellent control rates while minimizing the risk of acute and late toxicity.
University of Rochester James P. Wilmot Cancer Institute, Rochester
Duke University Medical Center, Durham
Washington University School of Medicine, St Louis
MD Anderson Cancer Center, Houston
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital, Weymouth
University Hospital Motol, Prague
University of Torino, Torino
Juntendo University, Tokyo
National Cancer Center of Singapore, Singapore
Yonsei University Health System, Seoul
Lead Sponsor
Duke University
OTHER